BBM H901
Alternative Names: BBM-H901Latest Information Update: 02 Apr 2023
At a glance
- Originator Belief Biomed
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Haemophilia B
Most Recent Events
- 02 Feb 2023 Institute of Hematology & Blood Diseases Hospital plans a phase I trial for Hemophilia B (Adolescents) in March 2023 (NCT05709288)
- 19 May 2022 Efficacy and adverse events data from an investigator initiated clinical trial for Haemophilia B released by Belief BioMed
- 03 Jan 2022 Clinical trials in Haemophilia B in China (IV) (CTR20212816)